Article published Jun 29, 2026. Prices below use latest available snapshots.
Question: IBB just printed a new all-time high (~$189.79, +463% all-time). Is the strength broad or carried by a handful of names — and which constituents are worth owning directly instead of (or alongside) the basket?
Verdict: Broad, but mid-cap / genomics / AI-bio-LED — not mega-cap-led. The move is healthy breadth (RSI 60–78 across almost the whole cohort, the opposite of the Mag 7's narrow concentration), but it is happening despite three of IBB's biggest anchors. Holding the ETF gives you those laggards as ~17% dead weight; the edge here is stock-picking the leaders.
What we're asking
User flagged IBB at all-time highs and the right instinct — "I'm guessing only some are doing well in the crowd." A cap-weighted ETF at an ATH can be a narrow mega-cap melt-up (fragile) or broad participation (durable). We decomposed it: pulled IBB's top-weight holdings and ranked the constituents we track by recent performance to see who is actually driving it, and which names clear our trend-hold bar for direct ownership.
What we found
1. The top-10 weights vs their performance
IBB top holdings (fund weights): GILD 7.4%, VRTX 7.4%, AMGN 7.1%, REGN 5.7%, ALNY 3.6%, ARGX 3.5%, NTRA 2.7%, BIIB 2.6%, RVMD 2.5%, ILMN 2.2% (top-10 ≈ 37% of the ETF).
| Holding | IBB wt | 30d | 3m | 1y | off-high | trend | read |
|---|---|---|---|---|---|---|---|
| VRTX | 7.4% | +14% | +13% | +9% | −2% | strong-up | working |
| AMGN | 7.1% | +10% | +4% | +25% | −8% | strong-up | working |
| BIIB | 2.6% | +13% | +15% | +63% | −1% | strong-up | working |
| ARGX | 3.5% | +9% | +30% | +68% | −2% | strong-up | leader (profitable) |
| NTRA | 2.7% | +24% | +46% | +68% | −1% | strong-up | leader (hot, weak quality) |
| RVMD | 2.5% | +18% | +108% | +409% | −0% | strong-up | leader (pre-revenue spec) |
| ILMN | 2.2% | +10% | +50% | +80% | −1% | strong-up | leader (profitable turnaround) |
| GILD | 7.4% | −3% | −7% | +16% | −20% | down | dead weight (#1 holding) |
| REGN | 5.7% | +5% | −16% | +16% | −23% | strong-down | dead weight |
| ALNY | 3.6% | −1% | −7% | −12% | −41% | strong-down | dead weight |
The headline: 7 of the top-10 are working, but the 3 that aren't are mega-cap anchors (GILD #1, REGN #4, ALNY #5 ≈ 17% of the ETF). IBB is at an ATH despite its single biggest holding (GILD) being in a downtrend and two more top-5 names strong-down. That's why the basket underperforms the leaders — you're carrying ~17% of dead weight.
2. Below the top-10, the move is broad — and it's the genomics / tools / AI-bio cohort
Ranking the broader ibb watchlist (37 names) by 30-day performance, almost everything is green with RSI 60–78 — genuine breadth. The leaders are the mid-cap genomics / life-science-tools / AI-bio cohort: ABSI +74%/30d (+311%/3m), TWST +45% (+127%), KYMR +39%, RARE +34%, PTGX +28% (+138%/1y), ABCL +26% (+148%/3m), TXG +26% (+88%), ICLR +25% (+65%), MRNA +51%/30d (+45%), MEDP +18%, plus the leaders above (ILMN/NTRA/RVMD/ARGX). That leading cohort is our biotech-capital-cycle lane (AI-bio platforms, genomics, lab-tools, CROs) — so the IBB breakout is, in large part, that thesis playing out at the index level.
The laggards/dead-weight, besides the 3 anchors: broken micro-caps (QSI, LAB, NAUT, SEER, CDXS), some gene-editing (EDIT −4%/30d, SRPT −3%/strong-down), and quality-questionable hot names (see NTRA below). RSI <55 club: GILD, ALNY, REGN, SRPT, BMRN, BNTX, NKTR, LEGN, EDIT — note the mega-cap anchors cluster here.
3. Coverage gap: three of the actual top-10 winners were untracked
Before this, RVMD, NTRA, and ARGX — three top-10 IBB holdings and three of the leaders — were not in any of our watchlists. We were blind to ~8.7% of the ETF and three of its best performers. All three are now in the new ibb watchlist (data fetched).
4. The stock-pick candidates (trend-hold lens), ranked
- ARGX (argenx) — the best stock-pick. Profitable (FY2025 EPS €19.57), revenue +64% YoY, 100% earnings beat rate, and RSI 62 — the least-extended of the leaders — strong-up, golden cross, −2% off high. A profitable, accelerating, not-overbought uptrend at a top-6 IBB weight. (IFRS filer; EDGAR XBRL is partial — see deep-dive.)
- ILMN (Illumina) — profitable turnaround. GAAP-profitable ($850M net, $5.45 EPS, +$1.08B operating cash flow), top-10 weight, recovered +80%/1y / +50%/3m into a golden-cross uptrend — but growth is slow (+4.8% YoY), so it's a margin/turnaround story, not a grower. Conviction medium.
- RVMD (Revolution Medicines) — speculative clinical lottery. Pre-revenue RAS-oncology biotech, $0 revenue, ~−$900M/yr burn against ~$1.9B liquidity (~2yr runway), but +409%/1y / +108%/3m on clinical anticipation, RSI 78 at highs. A real confirmed uptrend, but it's pure pipeline optionality at a parabolic price — research-only / speculative, not a fundamentals buy.
- NTRA (Natera) — hot tape, weak quality. $2.31B revenue (+38.8% YoY), operating-cash-flow positive (+$215M), but the leading composite is bearish (−0.8) — 25% earnings beat rate and insider selling — at RSI 77. Strong genomic-testing franchise, but the quality signals don't support chasing the extended tape. WATCH.
Deep-dives filed for all four (2026-06-29-{argx,ilmn,rvmd,ntra}-deep-dive.md). The biotech-capital-cycle mid-caps (ABSI/TWST/ABCL/TXG/ICLR/MEDP) already live in that perspective's coverage.
Verdict + reasoning
IBB's ATH is broad and largely healthy — but cap-weighting hands you the wrong names. Most constituents are participating (RSI 60–78, the inverse of Mag 7 narrowness), and the engine is the genomics / AI-bio / tools cohort that is our biotech-capital-cycle thesis. The catch is that ~17% of the ETF sits in three lagging mega-cap anchors (GILD/REGN/ALNY), so stock-picking the leaders beats holding the basket. For a trend-hold book: ARGX is the cleanest buy (profitable, accelerating, least-extended); ILMN the profitable-turnaround add; RVMD/NTRA are watch-only (spec / weak-quality despite hot tape); and the GILD/REGN/ALNY anchors are the ones to underweight or avoid. Keep the core IBB position for breadth if desired, but the alpha is in the leaders.
Sources
- New watchlist:
ibb(37 constituents we track + the RVMD/NTRA/ARGX coverage-gap adds). Price truth: ibb (settled Fri 2026-06-26). - Lane: 2026-06-04-biotech-capital-cycle — the leading cohort (AI-bio/genomics/tools) is this thesis; the IBB breakout is index-level confirmation of it.
- Deep-dives:
2026-06-29-argx-deep-dive.md,2026-06-29-ilmn-deep-dive.md,2026-06-29-rvmd-deep-dive.md,2026-06-29-ntra-deep-dive.md. - Method note: IBB has ~270 holdings; this decomposition covers the top-weight drivers + the ~37 investable constituents we track (which capture the overwhelming majority of the ETF's weight and all of its meaningful movers). The long tail of sub-0.3% holdings is not weight-relevant to the ETF's move.
Sources
- IBB top-holding weights:
IBB.funds_data.top_holdings(yfinance) — GILD 7.4% / VRTX 7.4% / AMGN 7.1% / REGN 5.7% / ALNY 3.6% / ARGX 3.5% / NTRA 2.7% / BIIB 2.6% / RVMD 2.5% / ILMN 2.2%. - Constituent price truth (settled Fri 2026-06-26 close): ibb (+ the per-watchlist biotech summaries) — the 30d/3m/1y/off-high/trend/RSI readings in the tables above.
- Candidate financials: the desk's own tooling (SEC EDGAR XBRL) +
leading {…}composites — detailed in each deep-dive.